U.S. Stem Cell is a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The Company's lead product candidate is MyoCell, an innovative clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells, or cells from a patient’s body, for the purpose of improving cardiac function in chronic heart failure patients.
Type | Public | |
HQ | Sunrise, FL, US | Map |
Website | us-stemcell.com |
USD | |
---|---|
Revenue (Q3, 2019) | 156.6k |
Gross profit (Q3, 2019) | 19.2k |
Gross profit margin (Q3, 2019), % | 12.3% |
Net income (Q3, 2019) | (1.6m) |
EBIT (Q3, 2019) | (1.6m) |
Market capitalization (25-Jan-2021) | 16.0m |
Closing stock price (25-Jan-2021) | 0.0 |
Cash (30-Sept-2019) | 78.1k |
EV | 17.4m |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 3.5k | 3.5k | 40.5k | 2.7k | 4.1k | 4.2k | 20.1k | 322.6k | 497.0k | 579.5k | 489.6k | 565.3k | 557.6k | 710.9k | 678.2k | 729.8k | 1.2m | 1.4m | 1.5m | 1.7m | 1.8m | 1.5m | 1.3m | 1.3m | 156.6k | |
Cost of goods sold | 139.0 | 139.0 | 417.0 | 94.4k | 107.1k | 523.2k | 247.6k | 223.6k | 243.9k | 154.4k | 235.4k | 332.5k | 344.6k | 400.6k | 482.9k | 503.8k | 567.2k | 544.4k | 522.1k | 506.0k | 137.4k | |||||
Gross profit | 3.4k | 3.4k | 40.1k | 228.1k | 389.9k | 56.3k | 241.9k | 341.7k | 313.7k | 556.6k | 442.9k | 397.3k | 810.4k | 985.3k | 1.0m | 1.2m | 1.3m | 959.5k | 786.7k | 792.0k | 19.2k | |||||
Gross profit Margin, % | 96% | 96% | 99% | 71% | 78% | 10% | 49% | 60% | 56% | 78% | 65% | 54% | 70% | 71% | 68% | 71% | 69% | 64% | 60% | 61% | 12% |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 34.2k | 2.8k | 69.9k | 35.2k | 4.8k | 239.0k | 172.8k | 6.7k | 219.0k | 91.2k | 46.6k | 71.0k | 93.5k | 65.7k | 275.4k | 130.8k | 246.0k | 619.1k | 929.7k | 956.6k | 1.7m | 1.7m | 1.4m | 749.4k | 587.5k | 78.1k |
Accounts Receivable | 304.0 | 1.1k | 1.7k | 220.0 | 8.9k | 48.8k | 105.6k | 153.9k | 78.5k | 98.5k | 93.8k | 48.8k | 41.6k | 33.9k | 59.9k | 33.2k | 115.0k | 75.9k | 47.4k | 32.5k | 64.2k | 12.2k | 20.2k | |||
Prepaid Expenses | 86.6k | 99.0k | 88.4k | 56.1k | 71.0k | 79.4k | 3.1k | 1.7k | 4.0k | 26.2k | 258.0 | 1.8k | 9.2k | 28.1k | 38.1k | 38.1k | 38.1k | 38.1k | 38.1k | |||||||
Inventories | 64.3k | 64.1k | 63.3k | 63.3k | 63.3k | 30.5k | 33.7k | 40.4k | 41.0k | 38.0k | 59.0k | 76.7k | 66.1k | 72.6k | 70.9k | 43.7k | 46.4k |
USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 |
---|---|---|---|---|---|---|---|---|
Net Income | (4.7m) | (4.0m) | (3.1m) | (2.3m) | (1.6m) | (2.1m) | (3.5m) | (2.2m) |
Depreciation and Amortization | 32.0k | 14.6k | 2.2k | 4.5k | 5.3k | 5.8k | 178.7k | 207.1k |
Inventories | 89.9k | 749.0 | 63.0k | (17.4k) | (24.8k) | (28.1k) | (22.9k) | |
Accounts Payable | 301.1k | 324.3k | (59.1k) | 858.4k | 434.5k | 10.5k | 469.2k | 426.3k |
USD | Q2, 2011 | Q3, 2011 | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (2.5m) | (3.7m) | (946.9k) | (1.7m) | (2.8m) | (518.9k) | (1.3m) | (2.4m) | 677.4k | 226.0k | (1.2m) | (1.0m) | (161.6k) | (283.0k) | (363.3k) | (716.2k) | (2.4m) | (2.5m) | (2.9m) | (3.8m) | (139.2k) | (1.4m) | (1.7m) | (673.2k) | (1.5m) | (3.2m) |
Depreciation and Amortization | 19.0k | 26.7k | 4.3k | 8.2k | 11.6k | 769.0 | 1.3k | 1.3k | 863.0 | 2.0k | 3.7k | 1.3k | 2.6k | 3.9k | 1.2k | 2.4k | 3.9k | 18.8k | 72.1k | 125.0k | 52.2k | 103.8k | 155.5k | 51.7k | 103.3k | 155.0k |
Inventories | 416.0 | 44.9k | 417.0 | 63.0k | 63.0k | 63.0k | (13.1k) | (16.3k) | (23.0k) | 1.2k | 4.2k | (16.8k) | (6.3k) | 4.3k | (2.3k) | 22.3k | 49.5k | 46.9k | ||||||||
Accounts Payable | 369.7k | 268.0k | 254.2k | 222.6k | 272.6k | (12.5k) | (71.1k) | (76.2k) | 172.8k | 255.4k | 628.7k | 114.5k | 243.0k | 324.0k | (62.9k) | 13.8k | 78.5k | 205.5k | 305.1k | 519.4k | 188.2k | 204.5k | 332.6k | 123.9k | 195.9k | 269.1k |
USD | Q2, 2011 |
---|---|
Debt/Assets | 1.3 x |
U.S. Stem Cell has 1.78k Twitter Followers. The number of followers has decreased 0.8% month over month and decreased 1% quarter over quarter
Who are U.S. Stem Cell key executives?
U.S. Stem Cell's key executives are William P. Murphy, Mike Tomás and Mark P Borman.
How many employees does U.S. Stem Cell have?
U.S. Stem Cell has 10 employees.
What is U.S. Stem Cell revenue?
Latest U.S. Stem Cell annual revenue is $6.7 m.
What is U.S. Stem Cell revenue per employee?
Latest U.S. Stem Cell revenue per employee is $670.1 k.
Who are U.S. Stem Cell competitors?
Competitors of U.S. Stem Cell include Enanta Pharmaceuticals, Immunic and Endologix.
Where is U.S. Stem Cell headquarters?
U.S. Stem Cell headquarters is located at 13794 NW 4th St #212, Sunrise.
Where are U.S. Stem Cell offices?
U.S. Stem Cell has an office in Sunrise.
How many offices does U.S. Stem Cell have?
U.S. Stem Cell has 2 offices.
Receive alerts for 300+ data fields across thousands of companies